GSK plc reported on February 5, 2024, that their DREAMM-7 phase III trial showed that the Blenrep combination significantly improved patient outcomes, nearly tripling progression-free survival (36.6 months vs. 13.4 months) in multiple myeloma treatment, with a 59% reduction in disease progression or death risk. These results suggest a strong potential for Blenrep to redefine treatment strategies for multiple myeloma.